ADT With and Without Xtandi in Men with Metastatic Hormone Sensitive Prostate Cancer: The ARCHES Trial

After a median follow-up of 14.4 months, the men who had Xtandi along with ADT experienced an improved radiographic progression-free survival advantage over those who had only ADT, regardless of their prior treatment. 

Short Term ADT with Radiotherapy As Salvage Treatment After Surgery: Update at 9 years of the GETUG-AFU 16 phase III Randomized Trial 

Findings confirm the better strategy for salvage therapy after failed surgery for prostate cancer is ADT along with radiotherapy,

Darolutamide - Great Results From The ARAMIS Trial For Men With M0 Prostate Cancer

The ARAMIS Trial showed that darolutamide increased overall survival for men with prostate cancer, it delayed the time to the use of cytotoxic chemotherapy as well as improving the important quality of life (QoL) measures of time to pain progression, and time to developing a symptomatic skeletal-related event.  

The ENZAMET Study: Adding Enzalutamide to ADT in Metastatic Hormone-Sensitive Prostate Cancer Extends Survival

The trial found that 80% of men with metastatic hormone-sensitiveprostate cancer who received enzalutamide (Xtandi) along with standard-of-care treatment (ADT) were alive after three years, compared with just 72% of men who received other nonsteroidal antiandrogens along with standard ADT therapy.

An Important Update on the Use of Radium in Combination with Zytiga and Xtandi

Make sure that you and your doctor use the bone-protecting approved medications (zoledronic acid or denosumab), especially for at least three weeks before using Xofigo (Radium-223).

When to Start ADT With A PSA Only Recurrence

Deferred hormone therapy (ADT) for in relapsing M0 (negative scans) prostate cancer patients is associated with prolonged overall survival (OS) measured from the time of local treatment, comparable to OS with salvage ADT in the contemporary experience.

Reporting on Apalutamide (Erleada) for Castrate Sensitive Prostate Cancer

The use of apalutamide (Erleada) improved radiographic progression-free survival with a 52% reduction in risk of death or radiographic progression; that benefit was observed across all subgroups analyzed in the TITAN TRIAL for men with progressing prostate cancer that is still hormone sensitive. The median radiographic progression-free survival was not reached in the apalutamide group and was 22.1 months in the placebo group.

What We Are Missing In Prostate Cancer Treatments

Prostate cancer treatments have been targeting the androgen receptor for over 80 years, and the vast majority of our new treatments also continue to target the androgen receptor.  Prostate cancer treatments have failed to include new classes of treatments when compared to other cancers. 

Lower Doses of Zytiga with Food

There was a small clinical trial, by Mark Ratain, M.D., of the University of Chicago, that suggests that it is possible to take a lower dose of Zytiga (abiraterone) along with a low-fat breakfast and achieve a response similar to the one we would expect to see with a full dose on an empty stomach.  

Insights into the Management of Oligometastatic Prostate Cancer

How best to treat oligometastatic prostate cancer is still not clear, but there are several on-going studies designed to determine what should be best practices.  Although not yet completed, these studies do indicate that metastasis-directed therapy (MDT) and local therapy targeted to the primary tumor (in the prostate gland) may be of benefit in the setting of oligometastatic disease. 

A Dive Into the Data Showing African American Men Do Better Than Caucasian Men with Provenge And All Men Live Longer If They Receive Provenge When Their PSA Scores Are Low

 African American men face many different health disparities with most of the disparities being weighed against them.  There is one notable exception, African American (AA) men have a huge, significant overall survival benefit when given Sipuleucel-T (Provenge) equal to 9.5 months over their Caucasian counterparts!

An Update of the NCCN Guidelines for the Treatment of Prostate Cancer

The National Comprehensive Cancer Network (NCCN) serves as a generally accepted cookbook or road map for doctors as they put together treatment plans for their patients.  The NCCN relies on evidence-based findings as well as FDA approvals.  Their guidelines create the standard of care for the treatment of serious disease, including cancer.

As it just did, the NCCN periodically releases updates to their guidelines for prostate cancer treatment.

First Data Release from The Metastatic Prostate Cancer Project

The project’s goal is to have thousands and thousands of men with metastatic prostate cancer share their medical records, their DNA and their tumor tissue so that we can understand the genomics of this disease, learn how it progresses and how resistance to treatments develop.